Page last updated: 2024-08-23

etoposide and gsk-2816126

etoposide has been researched along with gsk-2816126 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Azabdaftari, G; Dalimov, Z; Ellis, L; Hu, Q; Kirk, JS; Ku, S; Lasorsa, E; Pili, R; Ramakrishnan, S; Schaarschuch, K; Wang, J1

Other Studies

1 other study(ies) available for etoposide and gsk-2816126

ArticleYear
Top2a identifies and provides epigenetic rationale for novel combination therapeutic strategies for aggressive prostate cancer.
    Oncotarget, 2015, Feb-20, Volume: 6, Issue:5

    Topics: Animals; Antigens, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Cell Line, Tumor; Disease-Free Survival; DNA Topoisomerases, Type II; DNA-Binding Proteins; Enhancer of Zeste Homolog 2 Protein; Epigenesis, Genetic; Etoposide; Gene Expression Regulation, Neoplastic; Humans; Indoles; Male; Mice, Inbred C57BL; Poly-ADP-Ribose Binding Proteins; Polycomb Repressive Complex 2; Precision Medicine; Predictive Value of Tests; Prostatic Neoplasms; Pyridones; RNA, Messenger; Time Factors; Topoisomerase II Inhibitors; Up-Regulation; Xenograft Model Antitumor Assays

2015